Que pensez vous de la reponse de la FDA dans la approuval letter transmise à Merck concernant le Zioptan qui rappellons le est un "analog of prostaglandin F2a" tout comme le Xalatan et le Vesneo.
La FDA dit clairement :
Your application for ZIOPTAN was not referred to an FDA advisory committee because it is a
member of the class of ophthalmic prostaglandin analogs with similar potential risks and benefits
as other members in this class. The benefits and risks of using prostaglandin analogs to treat
elevated intraocular pressure have been previously discussed at a meeting of the Dermatologic
and Ophthalmic Drugs Advisory Committee on December 8, 1995, and the safety profile of
tafluprost did not raise any new significant safety issues. The clinical study design was similar
to other approved drugs in this class and we are not aware of any controversial issues that would
benefit from further advisory committee discussion.